Dados do Trabalho

Título

PREVALENCE OF PSYCHOSIS IN PARKINSON’S DISEASE - PRELIMINARY RESULTS OF A CROSS-SECTIONAL STUDY

Resumo

INTRODUCTION: Parkinson's disease (PD) is the second most common neurodegenerative disease. Its prevalence is close to 1% in the population over 60y and its incidence ranges from 8-18:100,000 person-years. Its etiology is multifactorial, with the main risk factor being aging. Although known for its motor symptoms, it encompasses a variety of non-motor symptoms such as psychosis, whose pathophysiology involves a combination of endogenous (disease/patient) and exogenous (treatment) factors. There is still no direct association between dopaminergic treatment and psychosis, but it is believed that it may be triggered or "accelerated" by it. Its management involves the gradual withdrawal of contributing drugs and the introduction of antipsychotics if necessary. Estimates of the prevalence of PDP vary widely in the literature. OBJECTIVE: To describe the prevalence of Parkinson’s disease Psychosis (PDP) and investigate patients' sociodemographic and clinical profile. METHODS: Ongoing descriptive, observational, cross-sectional study conducted in a Movement Disorders Outpatient Clinic in Salvador, Bahia. We included patients over 18y diagnosed with PD by the UK Brain Bank Criteria and excluded patients with psychiatric comorbidities. The study was approved by the local Ethics Committee. Data gathering involved questionnaires for clinical and sociodemographic evaluation. The NINDS/NIHM criteria, validated by the MDS, was used to diagnose PDP. The modified Hoehn & Yahr Scale (mH&Y) was used to stage the disease’s progression and the MMSE for cognitive assessment. RESULTS: Until now, the sample size has 23 patients. The median age was 63y (IIQ 52-72), with 65.2% being male, 39,1% self-reported as mixed-race and 52,2% were married. Regarding education, 43.5% had completed high school, and the median MMSE was 28 (IIQ 21-29). High Blood Pressure was the most common comorbidity (43.5%). The mean time of disease was 9.3±4.5 years and 34.8% had mH&Y of 2, while only 4.3% had mH&Y of 5. All patients were on levodopa therapy, 34.8% on dopamine agonist, 26.1% on amantadine, 21.7% on COMTi and 8.7% on MAO-Bi. The prevalence of psychosis in the sample studied is 8.7% (n=2). CONCLUSION: It is concluded that the prevalence of PDP in the studied sample so far is low, but corroborates with the current literature. We emphasize the importance of investigating non-motor symptoms in PD, often neglected, as evidenced by the low number of studies on PDP, especially in Brazil.

Palavras Chave

Área

Transtornos do Movimento